Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC vs EC-P in Low-Risk TNBC Predicted by mRNA-lncRNA Model
NCT06795503Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Feb 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of docetaxel, cyclophosphamide in triple-negative breast cancer (TNBC), sponsored by Fudan University. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
docetaxelcyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06795503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06795503.